Esculetin, a coumarin derivative, exerts in vitro and in vivo antiproliferative activity against hepatocellular carcinoma by initiating a mitochondrial-dependent apoptosis pathway

Brazilian Journal of Medical and Biological Research

Volumn 48, Issue 3, 2015, Pages 245-253

  Wang, J ^a   Lu, M L ^a   Dai, H L ^a   Zhang, S P ^a   Wang, H X ^a   Wei, N ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor activity; Apoptosis; Esculetin; Hepatocellular carcinoma; Mitochondrial dependent pathway

Indexed keywords

CASPASE 3; CASPASE 9; ESCULETIN; PROTEIN BAX; PROTEIN BCL 2; ANTIOXIDANT; UMBELLIFERONE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MEGADOSE; ENZYME ACTIVITY; GENETIC TRANSCRIPTION AND TRANSLATION; LIVER CELL CARCINOMA; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; LIVER NEOPLASMS; RANDOMIZATION;

MUS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; LIVER NEOPLASMS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RANDOM ALLOCATION; UMBELLIFERONES;

EID: 84924908431     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20144074     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90, doi: 10.3322/caac.20107.
2. Han KH, Park JY. Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010; 25: 1023-1025, doi: 10.1111/ j.1440-1746.2010.06359.x.
3. Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1294-1296, doi: 10.1056/NEJM199505113321910.
4. Hecht SS, Kenney PM, Wang M, Trushin N, Agarwal S, Rao AV, et al. Evaluation of butylated hydroxyanisole, myoinositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 1999; 137: 123-130, doi: 10.1016/S0304-3835(98)00326-7.
5. Witaicenis A, Seito LN, Di Stasi LC. Intestinal anti-inflammatory activity of esculetin and 4-methylesculetin in the trinitrobenzenesulphonic acid model of rat colitis. Chem Biol Interact 2010; 186: 211-218, doi: 10.1016/j.cbi.2010.03.045.
6. Yang J, Xiao YL, He XR, Qiu GF, Hu XM. Aesculetin-induced apoptosis through a ROS-mediated mitochondrial dysfunction pathway in human cervical cancer cells. J Asian Nat Prod Res 2010; 12: 185-193, doi: 10.1080/10286020903427336.
7. Subramaniam SR, Ellis EM. Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson’s disease. J Neurosci Res 2013; 91: 453-461, doi: 10.1002/jnr.23164.
8. Pan SL, Huang YW, Guh JH, Chang YL, Peng CY, Teng CM. Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats. Biochem Pharmacol 2003; 65: 1897-1905, doi: 10.1016/S0006-2952(03)00161-8.
9. Park SS, Park SK, Lim JH, Choi YH, Kim WJ, Moon SK. Esculetin inhibits cell proliferation through the Ras/ERK1/2 pathway in human colon cancer cells. Oncol Rep 2011; 25: 223-230.
10. Park C, Jin CY, Kim GY, Choi IW, Kwon TK, Choi BT, et al. Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. Toxicol Appl Pharmacol 2008; 227: 219-228, doi: 10.1016/j.taap.2007.10.003.
11. Kuo HC, Lee HJ, Hu CC, Shun HI, Tseng TH. Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells. Toxicol Appl Pharmacol 2006; 210: 55-62, doi: 10.1016/j.taap.2005.06.020.
12. Jing Wang, Hong-yu Li, Hong-Xin Wang. The separation and purification technology of esculetin from CORTEX FRAXINI. Chinese Traditional Patent Med 2009; 31: 294-296.
13. Wei N, Liu GT, Chen XG, Liu Q, Wang FP, Sun H. H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2. Biochem Pharmacol 2011; 82: 1593-1603, doi: 10.1016/j.bcp.2011.08.012.
14. Yokosuka T, Goto H, Fujii H, Naruto T, Takeuchi M, Tanoshima R, et al. Flow cytometric chemosensitivity assay using JC1, a sensor of mitochondrial transmembrane potential, in acute leukemia. Cancer Chemother Pharmacol 2013; 72: 1335-1342, doi: 10.1007/s00280-013-2303-x.
15. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005; 115: 2665-2672, doi: 10.1172/JCI26252.
16. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998; 95: 4997-5002, doi: 10.1073/pnas.95.9.4997.
17. Rubio V, Calvino E, Garcia-Perez A, Herraez A, Diez JC. Human acute promyelocytic leukemia NB4 cells are sensitive to esculetin through induction of an apoptotic mechanism. Chem Biol Interact 2014; 220C: 129-139, doi: 10.1016/j.cbi.2014.06.021.
18. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726, doi: 10.1038/nrc3599.
19. Lee SY, Lim TG, Chen H, Jung SK, Lee HJ, Lee MH, et al. Esculetin suppresses proliferation of human colon cancer cells by directly targeting beta-catenin. Cancer Prev Res 2013; 6: 1356-1364, doi: 10.1158/1940-6207.CAPR-13-0241.
20. Kok SH, Yeh CC, Chen ML, Kuo MY. Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells. Oral Oncol 2009; 45: 1067-1072, doi: 10.1016/j.oraloncology.2009.07.018.
21. Lacy A, O’Kennedy R. Studies on coumarins and coumarinrelated compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des 2004; 10: 3797-3811, doi: 10.2174/1381612043382693.
22. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003; 4: 721-729, doi: 10.1016/S1470-2045(03)01277-4.
23. Cullen SP, Martin SJ. Caspase activation pathways: some recent progress. Cell Death Differ 2009; 16: 935-938, doi: 10.1038/cdd.2009.59.
24. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008; 27: 6194-6206, doi: 10.1038/onc.2008.297.
25. Kumar S. Caspase function in programmed cell death. Cell Death Differ 2007; 14: 32-43, doi: 10.1038/sj.cdd.4402060.
26. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004; 73: 87-106, doi: 10.1146/annurev.biochem.73.011303.073706.
27. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63, doi: 10.1038/nrm3722.
28. Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 1998; 273: 7770-7775, doi: 10.1074/jbc.273.13.7770.
29. Low IC, Kang J, Pervaiz S. Bcl-2: a prime regulator of mitochondrial redox metabolism in cancer cells. Antioxid Redox Signal 2011; 15: 2975-2987, doi: 10.1089/ars.2010.3851.
30. Wong WW, Puthalakath H. Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life 2008; 60: 390-397, doi: 10.1002/iub.51.